Ross T. Murphy, MD Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Randall C. Starling, MD, MPH Head, Section of Heart Failure, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation
Address: Randall T. Starling, MD, Department of Cardiovascular Medicine, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Starling has indicated that he has received grant or research support from the Novartis, Scios, Fujisawa, Acorn, and Guidant corporations, serves as a consultant for the Novartis and Acorn corporations, and is on the speakers’ bureaus of the Glaxo and Novartis corporations.
ABSTRACTMany cases of cardiomyopathy have a genetic component: 90% of cases of hypertrophic cardiomyopathy are familial, and genetic factors may be responsible for 30% to 50% of cases of dilated cardiomyopathy. Clinical genetic testing for hypertrophic cardiomyopathy is becoming available, with significant implications for the clinician. This article gives an overview of how these genetic discoveries were made and how these new insights from genetics will affect clinical practice.